Are you low on this substance? You're at risk! It inhibits inflammation! Glutathione! Hubert Czer...

Czerniak explains that while the body can make glycine, the synthetic capacity is insufficient, leaving us in a perpetual 5-gram daily deficit. This deficit, if uncorrected, starves glutathione synthesis of a key building block, even if cysteine is abundant. He links this to collagen health (glycine is every third residue), insulin receptor architecture, and heme production. By supplementing glycine, we relieve that bottleneck. He doesn't prescribe a strict dose, but the 5 g shortfall quantifies the need. In the context of the animal and human studies he cites, glycine was given together with cysteine (as cystine) at a combined 100 mg/kg, which would include a substantial proportion of glycine. Thus, standalone glycine supplementation is logical as a baseline nutritional support, while combined precursor protocols provide more targeted therapy.

Czerniak details a series of experiments: animal studies where providing glycine and cysteine raised glutathione, lowered inflammatory markers, increased mitochondrial efficiency (favoring fat/ketone burning over glucose), and extended lifespan by 24%. He then highlights a 16-week human trial mirroring those results. Telomeres shortened more slowly, indicating delayed cellular aging, inflammatory cytokines dropped, muscle strength and endurance improved, and cardiac performance increased. He notes that mitochondria became more adept at burning fatty acids and ketones, whereas weak mitochondria prefer glucose—suggesting this protocol can shift metabolic health. However, he cautions that the effect is not permanent; once supplementation ceases, glutathione returns to pre-treatment levels within 6 weeks, implying that continued intake is necessary to maintain benefits. This is a potent but ephemeral intervention, requiring consistent commitment.

Czerniak argues that while cysteine is a component of glutathione, the synthesis rate is also tightly regulated by glycine. He notes that glycine is a small but mighty amino acid: it's every third amino acid in collagen, forms part of the insulin receptor (making it crucial for glucose metabolism), and combines with succinyl-CoA to initiate heme production. Without enough glycine, these systems falter. This insight recasts glutathione support as a two-precursor problem – both cysteine (ideally as cystine to survive digestion) and glycine must be supplied. He points to studies where administering both precursors together significantly raised reduced glutathione levels and improved multiple health outcomes, whereas focusing on cysteine alone may leave glycine as the hidden bottleneck. This is a fresh narrative that challenges many commercial glutathione supplements that emphasise only cysteine or NAC.

Czerniak personifies glyphosate as a 'Frankenstein of the 20th century' and invokes Professor Jan Narkiewicz-Jodko, who warned about GMOs and glyphosate. He explains that because glyphosate can replace glycine in proteins and receptors, it corrupts essential structures: if it replaces glycine in the insulin receptor, insulin resistance and diabetes may result; if it replaces glycine in the shikimate pathway of our gut bacteria, production of aromatic amino acids (phenylalanine, tryptophan, tyrosine) and folates is disrupted. He further argues that glyphosate may act on AMPA receptors (which use the amino acid AMPA, also structurally related) – these glutamate receptors are key for learning, concentration, and are hyperactive in autism. He suggests glyphosate exposure could be a hidden driver of rising autism rates, but laments that rigorous research is lacking. This is not merely a toxicity argument; it's a substitution-dysfunction model that integrates glyphosate into the very fabric of metabolic and neurological disease.

After explaining that we cannot simply drink regular glutathione because the digestive tract would neutralise and digest it, Czerniak pivots: 'If we want, we can consume it in such a special form.' He describes its taste as sour at first, with a not-very-pleasant smell, but after the initial negative sensation it becomes very tasty. He does not name the technology (likely liposomal or acetylated glutathione), but his personal description suggests he uses it himself. He then dismisses manufacturer marketing claims with a humorous 'I have deep contempt for what producers write,' implying that his own empirical experience and the scientific rationale matter more than brochures. This stance – endorsing a specific oral glutathione product while simultaneously deriding hype – creates a nuanced take: the substance works, don't be put off by marketing nonsense.